Literature DB >> 10941335

An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.

U Brockstedt1, M Gulyas, K Dobra, A Dejmek, A Hjerpe.   

Abstract

An immunocytochemical battery comprising 9 antibodies specifically distinguishes 80% of the epithelial malignant mesotheliomas from adenocarcinomas. The discriminatory power of antibodies to calretinin was tested together with this battery to determine whether the performance thereby could be improved. The study comprises 119 mesotheliomas of epithelial or mixed phenotype and 57 adenocarcinoma metastases in the pleural cavity. The differences between the 2 groups were highly significant for all recorded parameters, but typical reactivity for all parameters was seen in only 6 (5.0%) of the 119 mesotheliomas. An algorithm based on stepwise logistic regression was used to interpret divergent reaction patterns. Most diagnostic information was obtained with 8 of the parameters studied. The resulting algorithm identified almost 90% of the mesotheliomas with high specificity. The battery can be performed in 2 steps: several adenocarcinomas first are diagnosed with a few antibodies, applying the rest of the battery on the remaining unresolved cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10941335     DOI: 10.1309/QHCA-8594-TA7P-0DVQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  Use of Panel of Markers in Serous Effusion to Distinguish Reactive Mesothelial Cells from Adenocarcinoma.

Authors:  Devi Subbarayan; Jenna Bhattacharya; Poonam Rani; Bembem Khuraijam; Shyama Jain
Journal:  J Cytol       Date:  2019 Jan-Mar       Impact factor: 1.000

Review 2.  Immunocytochemistry of effusions: Processing and commonly used immunomarkers.

Authors:  Vinod B Shidham; Beata Janikowski
Journal:  Cytojournal       Date:  2022-01-31       Impact factor: 2.345

3.  Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Authors:  Helmut P Sandeck; Oluf D Røe; Kristina Kjærheim; Helena Willén; Erik Larsson
Journal:  Diagn Pathol       Date:  2010-07-06       Impact factor: 2.644

4.  Expression and diagnostic values of calretinin and CK5/6 in cholangiocarcinoma.

Authors:  Lanjing Zhang; Renee Frank; Emma E Furth; Amy F Ziober; Virginia A LiVolsi; Paul J Zhang
Journal:  Exp Hematol Oncol       Date:  2014-04-23

5.  Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics.

Authors:  Frederik Großerueschkamp; Thilo Bracht; Hanna C Diehl; Claus Kuepper; Maike Ahrens; Angela Kallenbach-Thieltges; Axel Mosig; Martin Eisenacher; Katrin Marcus; Thomas Behrens; Thomas Brüning; Dirk Theegarten; Barbara Sitek; Klaus Gerwert
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

Review 6.  Immunocytochemistry of effusion fluids: Introduction to SCIP approach.

Authors:  Vinod B Shidham; Lester J Layfield
Journal:  Cytojournal       Date:  2022-01-31       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.